Search Results for: "Clinic Roundup"
-
Clinic Roundup
MediciNova Inc., of San Diego, said results from its Phase II/III trial of MN-001 in 305 patients with moderate to severe interstitial cystitis failed to show a statistically significant clinical benefit compared to placebo in the study's primary endpoint of improved patient-rated Global Response AssessmentBioWorld Today | Wednesday, January 17, 2007 -
Clinic Roundup
Up to 258 subjects initially are set to be enrolled in each trial, and the primary endpoint will be the induction of disease remission 28 days after treatmentBioWorld Today | Wednesday, January 10, 2007 -
Clinic Roundup
Primary endpoints will focus on the safety and tolerability of ZEN-012 as well as establish the recommended Phase II dose and regimen...The primary endpoint is objective response rate (complete and partial responseBioWorld Today | Tuesday, January 9, 2007 -
Clinic Roundup
Aerovance Inc., of Berkeley, Calif., reported top-line results from a Phase IIa trial in asthma patients, showing that twice-daily use of inhaled Aerovant (IL-4 and IL-13 antagonist) reduced the severity of late asthmatic response by a statistically significant 72 percent compared to baseline, meeting the trial's primary endpointBioWorld Today | Thursday, January 4, 2007 -
Clinic Roundup
The study's primary endpoint is a reduction in menstrual bleeding, a common symptom of uterine fibroidsBioWorld Today | Friday, December 22, 2006 -
Clinic Roundup
That study will enroll between 18 and 35 patients and will measure response rate as determined by the Response Evaluation Criteria in Solid Tumors (RECIST) as the primary endpoint...Gilead Sciences Inc., of Foster City, Calif., said its Phase III AIR-CF2 study of aztreonam lysine for inhalation met its primary endpoint in cystic fibrosis patients who have pulmonary Pseudomonas aeruginosaBioWorld Today | Thursday, December 21, 2006 -
Clinic Roundup
The primary endpoint is sustained virologic response...Its primary endpoint will be the change from baseline in mean FEV1 (forced expiratory volume in 1 second) after a 15-minute infusion of MN-221, a highly selective Beta2-adrenergic receptor agonistBioWorld Today | Wednesday, December 20, 2006 -
Clinic Roundup
The compound demonstrated a statistically significant improvement compared to placebo in the primary endpoint, wake after sleep onset as measured at night one, for both doses studied (1mg: p=0.0053, 3mg: p<0.0001BioWorld Today | Tuesday, December 19, 2006 -
Clinic Roundup
The primary endpoint in the trial will be the median overall survival in the Neuradiab plus standard-of-care arm compared to patients receiving standard of care aloneBioWorld Today | Monday, December 18, 2006 -
Clinic Roundup
The primary endpoint is overall survivalBioWorld Today | Wednesday, December 13, 2006 -
Clinic Roundup
The trial results showed a 2 mm Hg difference in both the average systolic and diastolic blood pressure in favor of naproxcinod, in terms of the mean change from baseline as measured by ABPM, but the difference did not reach statistical significance for systolic blood pressure, the primary endpoint of the trial (p=0.101BioWorld Today | Tuesday, December 12, 2006 -
Clinic Roundup
GTx Inc., of Memphis, Tenn., said ostarine, a first-in-class selective androgen receptor modulator (SARM), met its primary endpoint in a Phase II trial, but the company plans to start a Phase IIb trial by next summer to further confirm efficacy in cancer cachexia patients...The difference did not reach statistical significance for systolic blood pressure, the primary endpoint, but statistical significance was achieved for diastolic blood pressure, a secondary endpointBioWorld Today | Monday, December 11, 2006 -
Clinic Roundup
Somaxon Pharmaceuticals Inc., of San Diego, said oral nalmefene, its impulse-control disorder drug, missed its primary endpoint in a Phase II/III trial in patients diagnosed with pathological gamblingBioWorld Today | Wednesday, December 6, 2006 -
Clinic Roundup
The 31-patient trial will measure the primary endpoints of reduction in PSA levels, reduction in tumor size and disease-free survival...The trial is designed to evaluate the rate of complete remission as its primary endpoint, with secondary endpoints measuring duration of remission, overall survival and safetyBioWorld Today | Tuesday, December 5, 2006 -
Clinic Roundup
The primary endpoints are best overall antitumor response rate and the percentage of patients surviving two yearsBioWorld Today | Thursday, November 30, 2006 -
Clinic Roundup
The primary endpoint is disease progression according to the Unified Parkinson's Disease Rating Scale...The primary endpoint is overall response measured as either complete response or complete response with incomplete platelet recoveryBioWorld Today | Tuesday, November 28, 2006 -
Clinic Roundup
study is expected to involve more than 200 patients randomized on a 2:1 basis to receive either AA4500 or placebo, with the primary endpoint of reducing the contracture angle to within 0 to 5 degrees of normal as measured by digital goniometry...Pharmacyclics previously reported results from both Phase III studies, in which the drug failed to meet the primary endpoints, but the company reported findings that suggested Xcytrin in combination with WBRT might be statistically significantBioWorld Today | Tuesday, November 21, 2006 -
Clinic Roundup
The primary endpoint is to assess total sleep time, determined by polysomnographyBioWorld Today | Monday, November 20, 2006 -
Clinic Roundup
The primary endpoint is the proportion of confirmed responses as defined by the International Working Group, and secondary endpoints include time to progression, overall survival, duration of response and toxicity...The primary endpoint is the change from baseline in mean FEV1 (forced expiratory volume in one second) after 12 weeksBioWorld Today | Friday, November 17, 2006 -
Clinic Roundup
The study's primary endpoint is to determine the proportion of patients with resolution of their abnormal Pap smear during the 12-week study durationBioWorld Today | Thursday, November 16, 2006
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.